Clovis Oncology Inc (NASDAQ:CLVS)
| 5.67 Delayed Data As of 4:03pm ET |  -0.11 / -1.90%Today’s Change | 4.08 Today|||52-Week Range 11.10 | +18.13% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $624.6M |
Company Description
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
Contact Information
Clovis Oncology, Inc. 5500 Flatiron Parkway Boulder Colorado 80301 |
Employees
Shareholders
| Individual stakeholders | 4.14% |
| Mutual fund holders | 26.31% |
| Other institutional | 22.48% |
Top Executives
| Patrick J. Mahaffy | President, Chief Executive Officer & Director |
| Daniel W. Muehl | Chief Financial Officer & Executive Vice President |
| Lindsey Rolfe | Chief Medical Officer & Executive VP-Clinical |
| Thomas Fuglsang Harding | Chief Scientific Officer & Executive VP |
| Gillian C. Ivers-Read | Chief Regulatory Officer & Executive VP |
